Recombinant human plasma gelsolin

DRUG3 trials

Sponsors

Bioaegis Therapeutics Inc., BioAegis Therapeutics Inc.

Conditions

Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other InfectionsCommunity-acquired PneumoniaHealthyVolunteers

Phase 1

A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP

CompletedNCT03466073

BioAegis Therapeutics Inc.Community-acquired Pneumonia

Start: 2018-08-28End: 2019-04-02Updated: 2020-01-27

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

CompletedNCT05789745

BioAegis Therapeutics Inc.Healthy, Volunteers

Start: 2023-03-14End: 2023-05-24Updated: 2024-09-19

Phase 2

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections

RecruitingCTIS2023-510109-16-00

Bioaegis Therapeutics Inc.Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other Infections

Start: 2025-01-06Target: 372Updated: 2026-01-19

Related Papers

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu-pGSN) Following Intravenous Administration to Healthy Volunteers

medRxiv2026-03-30

Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.

2020-09-218 citations